CROMA at ESCRS

Article

During this year?s ESCRS in Vienna CROMA will highlight its history of 35 years as a key player in ophthalmology.

During this year´s ESCRS in Vienna CROMA will highlight its history of 35 years as a key player in ophthalmology. Having started from a small pharmacy, the family-owned company reached the level of big international competitors, constantly developing innovative and unique products for markets all over the world.

Currently, CROMA is performing clinical studies, involving a new product, based on the so-called Thiomers, a unique technology combining macromolecules such as hyaluronic acid to a human amino acid (cysteine) for different ophthalmic applications. First results will be presented during the CROMA satellite symposium.

In the field of intraocular lenses, CROMA is launching two new models in 2011. The new hydrophobic blue-light filtering IOL “EYE-Cee One” has been successfully introduced in May. First clinical experiences will be shared during the ESCRS lunch symposium. CROMA will further make use of the ESCRS in Vienna to internationally launch its new multifocal IOL.

CROMA satellite symposium:

“Amazing Advances in Ocular Excellence”
Sunday, 18th September, 2011
1:00 pm – 2:00 pm
Room Stolz 1

CROMA - Bausch and Lomb joint satellite symposium:

“Bromfenac, a new potent Tool in Inflammation Control post cararact surgery”
Sunday, 18th September, 2011
1:00 pm – 2:00 pm
Room Strauss 3

Click here to register online.

Click here to email CROMA

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.